↓ Skip to main content

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer

Overview of attention for article published in Journal of Clinical Investigation, June 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news
16 news outlets
blogs
1 blog
twitter
24 X users
patent
24 patents

Citations

dimensions_citation
332 Dimensions

Readers on

mendeley
350 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
Published in
Journal of Clinical Investigation, June 2016
DOI 10.1172/jci81603
Pubmed ID
Authors

Kipp Weiskopf, Nadine S. Jahchan, Peter J. Schnorr, Sandra Cristea, Aaron M. Ring, Roy L. Maute, Anne K. Volkmer, Jens-Peter Volkmer, Jie Liu, Jing Shan Lim, Dian Yang, Garrett Seitz, Thuyen Nguyen, Di Wu, Kevin Jude, Heather Guerston, Amira Barkal, Francesca Trapani, Julie George, John T. Poirier, Eric E. Gardner, Linde A. Miles, Elisa de Stanchina, Shane M. Lofgren, Hannes Vogel, Monte M. Winslow, Caroline Dive, Roman K. Thomas, Charles M. Rudin, Matt van de Rijn, Ravindra Majeti, K. Christopher Garcia, Irving L. Weissman, Julien Sage

Abstract

Small-cell lung cancer (SCLC) is a highly aggressive subtype of lung cancer with limited treatment options. CD47 is a cell-surface molecule that promotes immune evasion by engaging signal-regulatory protein alpha (SIRPα), which serves as an inhibitory receptor on macrophages. Here, we found that CD47 is highly expressed on the surface of human SCLC cells; therefore, we investigated CD47-blocking immunotherapies as a potential approach for SCLC treatment. Disruption of the interaction of CD47 with SIRPα using anti-CD47 antibodies induced macrophage-mediated phagocytosis of human SCLC patient cells in culture. In a murine model, administration of CD47-blocking antibodies or targeted inactivation of the Cd47 gene markedly inhibited SCLC tumor growth. Furthermore, using comprehensive antibody arrays, we identified several possible therapeutic targets on the surface of SCLC cells. Antibodies to these targets, including CD56/neural cell adhesion molecule (NCAM), promoted phagocytosis in human SCLC cell lines that was enhanced when combined with CD47-blocking therapies. In light of recent clinical trials for CD47-blocking therapies in cancer treatment, these findings identify disruption of the CD47/SIRPα axis as a potential immunotherapeutic strategy for SCLC. This approach could enable personalized immunotherapeutic regimens in patients with SCLC and other cancers.

X Demographics

X Demographics

The data shown below were collected from the profiles of 24 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 350 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 5 1%
Sweden 1 <1%
Germany 1 <1%
Austria 1 <1%
Unknown 342 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 72 21%
Researcher 66 19%
Student > Master 33 9%
Student > Bachelor 24 7%
Student > Doctoral Student 20 6%
Other 51 15%
Unknown 84 24%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 76 22%
Medicine and Dentistry 62 18%
Agricultural and Biological Sciences 35 10%
Immunology and Microbiology 31 9%
Pharmacology, Toxicology and Pharmaceutical Science 18 5%
Other 31 9%
Unknown 97 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 157. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 January 2024.
All research outputs
#249,079
of 24,657,405 outputs
Outputs from Journal of Clinical Investigation
#256
of 16,911 outputs
Outputs of similar age
#5,031
of 359,804 outputs
Outputs of similar age from Journal of Clinical Investigation
#8
of 96 outputs
Altmetric has tracked 24,657,405 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 16,911 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 16.5. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 359,804 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 96 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.